Case | 1 June 2026
Setterwalls advises Cantargia in connection with a capital raise of approximately SEK 124 million and entering into a loan agreement
Setterwalls advises Cantargia AB (publ) (“Cantargia”), listed on Nasdaq Stockholm, in connection with a rights issue of shares of approximately SEK 124 million and entering into a loan agreement with Fenja Capital II A/S of up to SEK 75 million.
The transaction strengthens the company’s financial position and supports the continued clinical development of Cantargia’s antibody-based treatments for life-threatening diseases.
Cantargia is a clinical-stage biotechnology company developing antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP. The company’s shares are listed on Nasdaq Stockholm and is headquartered in Lund, Sweden.
Practice areas:
